452 online
 
Most Popular Choices
Share on Facebook 77 Printer Friendly Page More Sharing Summarizing
OpEdNews Op Eds    H3'ed 8/28/22

Growing support globally to end HIV medicine stockouts in India

By       (Page 3 of 3 pages) Become a premium member to see this article and all articles as one long page.   No comments

Citizen News Service - CNS
Follow Me on Twitter     Message Citizen News Service - CNS
Become a Fan
  (2 fans)

L Deepak Singh rightly said that despite pouring in reports from different states of India of stockouts or shortages of antiretroviral medicines, "the official response of NACO and State AIDS Control Societies is that, 'there is no stockout of antiretroviral medicines. We demand justice for the marginalised people living with HIV whose lives hang in balance."

Hari Singh, Vice Chairman of Global Alliance for Human Rights, India, wrote to the government: "Due to the stockout issue, lives of many persons living with HIV including children are in danger as they cannot afford these drugs, and due to this, many are added to the 'Lost to Follow Up (LFU)' list and many are facing serious life-threatening illnesses. This will also affect the prevention efforts."

As on 27th August 2022, it has been 38-days and nights non-stop sit-in that people living with HIV have steadfastly staged outside the offices of national AIDS programme of government of India in national capital Delhi.

Keep the promise

Government's own promise to end AIDS and 95-95-95 goals of 2025 will not be met if the basic demands of people living with HIV are not met. Uninterrupted supply of HIV medicines is one of the essential cog-in-the-wheels to help people adhere to the lifelong and lifesaving antiretroviral therapy, stay virally suppressed, live fully and healthily, and become untransmittable as undetectable equals untransmittable. But if supplies are intermittent or supply chain issues continue to plague India's AIDS programme, then how will we deliver on the promise to end AIDS in next 100 months (by 2030)?

Bobby Ramakant - CNS (Citizen News Service)

(Bobby Ramakant is the Editor of CNS (Citizen News Service) and a World Health Organization (WHO) Director General's WNTD Awardee 2008. Follow him on Twitter @CNS_Health or read www.bit.ly/BobbyRamakant)

- Shared under Creative Commons (CC)

Next Page  1  |  2  |  3

(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).

Rate It | View Ratings

Citizen News Service - CNS Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Citizen News Service (CNS) specializes in in-depth and rights-based, health and science journalism. For more information, please contact: www.citizen-news.org or @cns_health or www.facebook.com/cns.page
Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines

 
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEd News Newsletter

Name
Email
   (Opens new browser window)
 

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

The chasm between TB and HIV continues

Management of respiratory diseases beyond drugs: Pulmonary Rehabilitation

Oxygen therapy is like a prescription drug: Use it rationally

New funding boosts research for controlling TB, malaria, dengue and leishmaniasis

Why are shorter, safer and more effective treatments for drug-resistant TB not being rolled out?

Journey of a TB survivor from pain to strength

To View Comments or Join the Conversation:

Tell A Friend